AU2016217800B2 - Cysteine protease - Google Patents

Cysteine protease Download PDF

Info

Publication number
AU2016217800B2
AU2016217800B2 AU2016217800A AU2016217800A AU2016217800B2 AU 2016217800 B2 AU2016217800 B2 AU 2016217800B2 AU 2016217800 A AU2016217800 A AU 2016217800A AU 2016217800 A AU2016217800 A AU 2016217800A AU 2016217800 B2 AU2016217800 B2 AU 2016217800B2
Authority
AU
Australia
Prior art keywords
lys
gly
leu
asp
asn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016217800A
Other languages
English (en)
Other versions
AU2016217800A1 (en
Inventor
Sofia JARNUM
Christian Kjellman
Emma NORDAHL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hansa Biopharma AB
Original Assignee
Hansa Biopharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hansa Biopharma AB filed Critical Hansa Biopharma AB
Publication of AU2016217800A1 publication Critical patent/AU2016217800A1/en
Assigned to Hansa Biopharma AB reassignment Hansa Biopharma AB Amend patent request/document other than specification (104) Assignors: HANSA MEDICAL AB
Application granted granted Critical
Publication of AU2016217800B2 publication Critical patent/AU2016217800B2/en
Priority to AU2021266293A priority Critical patent/AU2021266293B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
AU2016217800A 2015-02-12 2016-02-12 Cysteine protease Active AU2016217800B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021266293A AU2021266293B2 (en) 2015-02-12 2021-11-11 Cysteine protease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201502306A GB201502306D0 (en) 2015-02-12 2015-02-12 Protein
GB1502306.2 2015-02-12
PCT/EP2016/053052 WO2016128558A1 (en) 2015-02-12 2016-02-12 Cysteine protease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021266293A Division AU2021266293B2 (en) 2015-02-12 2021-11-11 Cysteine protease

Publications (2)

Publication Number Publication Date
AU2016217800A1 AU2016217800A1 (en) 2017-08-10
AU2016217800B2 true AU2016217800B2 (en) 2021-08-12

Family

ID=52781456

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016217800A Active AU2016217800B2 (en) 2015-02-12 2016-02-12 Cysteine protease
AU2021266293A Active AU2021266293B2 (en) 2015-02-12 2021-11-11 Cysteine protease

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021266293A Active AU2021266293B2 (en) 2015-02-12 2021-11-11 Cysteine protease

Country Status (23)

Country Link
US (5) US10696959B2 (OSRAM)
EP (2) EP4108768A1 (OSRAM)
JP (1) JP6961486B2 (OSRAM)
KR (1) KR102524613B1 (OSRAM)
CN (2) CN114231512B (OSRAM)
AU (2) AU2016217800B2 (OSRAM)
BR (1) BR112017017284A2 (OSRAM)
CA (1) CA2976003A1 (OSRAM)
CL (1) CL2017002065A1 (OSRAM)
CO (1) CO2017009061A2 (OSRAM)
DK (1) DK3256580T3 (OSRAM)
EA (1) EA035130B1 (OSRAM)
ES (1) ES2927234T3 (OSRAM)
GB (1) GB201502306D0 (OSRAM)
IL (1) IL253938B (OSRAM)
LT (1) LT3256580T (OSRAM)
MX (1) MX390806B (OSRAM)
MY (1) MY188696A (OSRAM)
PL (1) PL3256580T3 (OSRAM)
PT (1) PT3256580T (OSRAM)
SG (1) SG11201706346QA (OSRAM)
WO (1) WO2016128558A1 (OSRAM)
ZA (1) ZA201705113B (OSRAM)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502306D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
JP2021519581A (ja) 2018-04-03 2021-08-12 ストライドバイオ，インコーポレイテッド 抗体を回避するウイルスベクター
SG11202009452WA (en) 2018-04-03 2020-10-29 Stridebio Inc Antibody-evading virus vectors
JP7425738B2 (ja) 2018-04-03 2024-01-31 ギンコ バイオワークス インコーポレイテッド 眼組織を標的とするウイルスベクター
AU2020241888A1 (en) 2019-03-21 2021-09-30 Ginkgo Bioworks, Inc. Recombinant adeno-associated virus vectors
WO2021067598A1 (en) 2019-10-04 2021-04-08 Ultragenyx Pharmaceutical Inc. Methods for improved therapeutic use of recombinant aav
KR20220083714A (ko) 2019-10-17 2022-06-20 스트라이드바이오 인코포레이티드 니만-피크 질환 c형의 치료를 위한 아데노-연관 바이러스 벡터
KR20230152810A (ko) * 2019-12-06 2023-11-03 리제너론 파아마슈티컬스, 인크. 항-vegf 단백질 조성물 및 이를 생산하는 방법
BR112022015921A2 (pt) 2020-02-14 2022-10-04 Ultragenyx Pharmaceutical Inc Terapia gênica para tratar o transtorno de deficiência de cdkl5
GB202002072D0 (en) 2020-02-14 2020-04-01 Hansa Biopharma AB immunoglobulin detection and associated therapies
GB202003129D0 (en) * 2020-03-04 2020-04-15 Hansa Biopharma AB Conditioning regimen for transplant of stem cells
JP2023525034A (ja) 2020-05-08 2023-06-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法
GB202007434D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Methods
GB202007431D0 (en) 2020-05-19 2020-07-01 Hansa Biopharma AB Cysteine protease
WO2021244628A1 (zh) 2020-06-05 2021-12-09 上海宝济药业有限公司 一种酶和病毒的药物组合及其应用
JP2023532219A (ja) * 2020-06-18 2023-07-27 上海宝済薬業有限公司 免疫グロブリン分解酵素ＩｄｅＥの突然変異体
AR123288A1 (es) 2020-08-19 2022-11-16 Stridebio Inc Vectores de virus adenoasociados para el tratamiento del síndrome de rett
IL301955A (en) 2020-10-07 2023-06-01 Asklepios Biopharmaceutical Inc Therapeutic delivery of an adeno-related protein-related protein (FKRP) virus for the treatment of dystroglycanopathy disorders, including limb girdle 21
CA3216491A1 (en) 2021-04-16 2022-10-20 Asklepios Biopharmaceutical, Inc. Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
EP4079848A1 (en) 2021-04-22 2022-10-26 Genovis Ab Immunoglobulin cleaving enzyme
WO2023019168A1 (en) 2021-08-11 2023-02-16 Ultragenyx Pharmaceutical Inc. Compositions and methods for treating a muscular dystrophy
AU2022385450A1 (en) 2021-11-15 2024-06-13 Hansa Biopharma AB Methods for enhancing adoptive cell transfer immunotherapies
US20250145730A1 (en) 2021-12-16 2025-05-08 Shanghai Bao Pharmaceuticals Co., Ltd. Anti-immunoglobulin degrading enzyme-digested fc variant
TW202334183A (zh) 2021-12-22 2023-09-01 大陸商上海寶濟藥業有限公司 免疫球蛋白降解酶ｌｄｅＥ的突變體的用途
EP4275701A1 (en) 2022-05-13 2023-11-15 Hansa Biopharma AB Conditioning regimen for cell transplant
EP4302770A1 (en) 2022-07-08 2024-01-10 Hansa Biopharma AB Regimen for enzymatic desensitisation
EP4349365A1 (en) 2022-10-07 2024-04-10 Hansa Biopharma AB Co-treatment for gene therapy
CN115873833B (zh) * 2022-11-08 2024-08-16 上海泰昶生物技术有限公司 生产免疫球蛋白g降解酶的工程菌株和工艺
CN115998690B (zh) * 2022-11-10 2024-07-26 上海泰昶生物技术有限公司 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺
US12091694B2 (en) 2022-11-18 2024-09-17 Seismic Therapeutic, Inc. Fc fusion molecules and uses thereof
EP4646476A1 (en) 2023-01-06 2025-11-12 Seismic Therapeutic, Inc. Protease variants and uses thereof
WO2025072144A1 (en) * 2023-09-27 2025-04-03 Osprey Biopharmaceuticals, Inc. Polypeptides having human igg cleavage activity
WO2025256977A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Novel igm and igg cleaving enzymes
WO2025256978A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Variants of igm and igg cleaving enzymes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006131347A2 (en) * 2005-06-09 2006-12-14 Hansa Medical Ab Use of the ides proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
AU1686302A (en) 2000-12-21 2002-07-01 Shire Biochem Inc Streptococcus pyogenes antigens and corresponding dna fragments
GB0130228D0 (en) * 2001-12-18 2002-02-06 Hansa Medica Ab Protein
CN100379448C (zh) * 2002-11-29 2008-04-09 森永乳业株式会社 蛋白酶抑制剂
EP1601770B1 (en) * 2003-03-04 2009-09-02 Intercell AG Streptococcus pyogenes antigens
GB0511769D0 (en) * 2005-06-09 2005-07-20 Hansa Medical Ab Treatment
US7544577B2 (en) 2005-08-26 2009-06-09 International Business Machines Corporation Mobility enhancement in SiGe heterojunction bipolar transistors
EP2190984B1 (en) * 2007-09-14 2013-09-04 Genovis Ab Methods and kits for purification and detection of glycosylated IgG
AU2008336295B2 (en) * 2007-12-13 2013-07-11 Intervacc Ab Improved immunizing composition
ES2388017T3 (es) 2007-12-21 2012-10-05 Roche Glycart Ag Ensayo de estabilidad de anticuerpos
EP2394173B1 (en) * 2009-02-09 2015-03-25 Roche Glycart AG Immunoglobulin glycosylation pattern analysis
ES2948841T3 (es) 2010-05-26 2023-09-20 Intervacc Ab Vacuna contra infecciones estreptocócicas basada en proteínas de fusión recombinantes
GB201115841D0 (en) * 2011-09-13 2011-10-26 Genovis Ab Protein and method
GB201201314D0 (en) 2012-01-26 2012-03-07 Isis Innovation Composition
CN103214549B (zh) * 2013-01-15 2015-08-05 珠海市丽珠单抗生物技术有限公司 一种还原免疫球蛋白的方法及其试剂盒
GB201316744D0 (en) 2013-09-20 2013-11-06 Genovis Ab Method
GB201413240D0 (en) 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502306D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006131347A2 (en) * 2005-06-09 2006-12-14 Hansa Medical Ab Use of the ides proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection

Also Published As

Publication number Publication date
ZA201705113B (en) 2024-01-31
NZ733959A (en) 2024-07-26
JP6961486B2 (ja) 2021-11-05
EA035130B1 (ru) 2020-04-30
MY188696A (en) 2021-12-23
IL253938A0 (en) 2017-10-31
MX2017010390A (es) 2017-12-07
AU2021266293B2 (en) 2024-10-03
US12359183B2 (en) 2025-07-15
BR112017017284A2 (pt) 2018-04-17
AU2021266293A1 (en) 2021-12-09
US10696959B2 (en) 2020-06-30
US20200283749A1 (en) 2020-09-10
CL2017002065A1 (es) 2018-04-02
ES2927234T3 (es) 2022-11-03
US11214784B2 (en) 2022-01-04
US20250304937A1 (en) 2025-10-02
PT3256580T (pt) 2022-10-03
LT3256580T (lt) 2022-10-10
KR20170116137A (ko) 2017-10-18
AU2016217800A1 (en) 2017-08-10
CN107532156A (zh) 2018-01-02
SG11201706346QA (en) 2017-09-28
EP3256580A1 (en) 2017-12-20
US20230357741A1 (en) 2023-11-09
EA201791773A1 (ru) 2018-02-28
US11667905B2 (en) 2023-06-06
MX390806B (es) 2025-03-21
PL3256580T3 (pl) 2022-11-28
CO2017009061A2 (es) 2018-01-16
CA2976003A1 (en) 2016-08-18
DK3256580T3 (en) 2022-10-03
KR102524613B1 (ko) 2023-04-21
IL253938B (en) 2020-01-30
US20180023070A1 (en) 2018-01-25
GB201502306D0 (en) 2015-04-01
JP2018506286A (ja) 2018-03-08
US20220170004A1 (en) 2022-06-02
EP3256580B1 (en) 2022-07-06
CN114231512B (zh) 2025-02-14
CN114231512A (zh) 2022-03-25
WO2016128558A1 (en) 2016-08-18
EP4108768A1 (en) 2022-12-28

Similar Documents

Publication Publication Date Title
AU2021266293B2 (en) Cysteine protease
US20230302100A1 (en) Cysteine protease
US12460194B2 (en) Cysteine protease
EA049939B1 (ru) Цистеин-протеаза
HK1240611B (en) Cysteine protease
HK1240611A1 (en) Cysteine protease
HK1240619A1 (en) Cysteine protease
HK1240619B (en) Cysteine protease

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: HANSA BIOPHARMA AB

Free format text: FORMER NAME(S): HANSA MEDICAL AB

FGA Letters patent sealed or granted (standard patent)